T-Cell Vaccination in Multiple Sclerosis (MS)

The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial

The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.

Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones.

Clinical immunologic and neuroradiologic evaluation.

Inclusion Criteria:

• Definite MS (post criteria)
• Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
• Disease duration > 1 year
• Expanded Disability Status Scale (EDSS) between 0-6
• Brain magnetic resonance imaging (MRI) compatible with MS
• Not involved in any other clinical trials
• No other systemic disease

Exclusion Criteria:

• Does not comply with the above